PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies
Poly-ADP-ribose polymerase (PARP) inhibitors represent a novel class of anticancer agents that leverage the principle of synthetic lethality to induce tumor cell death by disrupting defective DNA repair pathways. PARP inhibitors have demonstrated strong preclinical activity in tumors with homologous recombination (HR)...